Researchers review the role of microfluidic chip models in understanding neurodegenerative diseases, offering insights into the disease mechanisms and potential for drug development through innovative
Study using data from the FAMiLI project reveals socioeconomic status (SES) significantly impacts the gut microbiome’s diversity and composition across a diverse U.S. population, underscoring
Psychedelic drug developer Gilgamesh Pharmaceuticals has scooped a grant worth $14m from the National Institute on Drug Abuse (NIDA) to develop its ibogaine analog, GM-3009,
What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And is MASH still a big deal? We cover all that
The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH. The pill, called
The start of the COVID-19 pandemic led to unprecedented exposure to stressors driven by fears of a novel and deadly disease, intense uncertainty, and resulting
Although COVID-19 has faded from the headlines, SARS-CoV-2 – the coronavirus behind the pandemic – is still rampantly infecting people around the world.
Gut bacteria and a diet rich in the amino acid tryptophan can play a protective role against pathogenic E. coli, which can cause severe stomach
TORONTO – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (‘Cybin’ or the ‘Company’), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative
Clearmind Medicine Inc. announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use